EUVIMEDEUVIMED entdecken
Crossref

Post-marketing safety evaluation and objective benefit-risk assessment of sublingual immunotherapy tablets in allergic rhinitis

Eleonora Castellana, Maria Rachele Chiappetta

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-06 · 399 (9) · 14595-14599

DOI: 10.1007/s00210-026-05307-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 08.04.2026. Verfasst von Eleonora Castellana und 1 weiteren Autor:innen. Beteiligte Einrichtung: Azienda Ospedaliero Universitaria Città Della Salute E Della Scienza Di Torino, Hospital Pharmacy, C.So Bramante 88, Turin, 10135, Piedmont, Italy. e…. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Sublingual Immunotherapy. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the post-marketing safety profile and benefit-risk balance of FDA-approved sublingual immunotherapy (SLIT) tablets for allergic rhinitis. A retrospective pharmacovigilance analysis was conducted using FAERS data (2014-2025). Reports including Oralair®, Grazax®/Grastek®, Ragwitek®, and Odactra® as suspected drugs were analyzed descriptively. A total of 1509 cases were identified, mostly in adults. Most adverse events (59.17%) were non-serious. The most common reactions were throat irritation, oral pruritus, dyspnoea, pruritus, and throat tightness. Serious outcomes were uncommon, including hospitalization (7.45%), life-threatening events (3.12%), and death (0.25%). The safety profile was consistent with clinical trial data. SLIT tablets demonstrate a favorable safety profile with a positive benefit-risk balance. They represent an effective and generally safe option for allergic rhinitis when appropriate patient selection and clinical monitoring are ensured.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhinitis, AllergicSublingual ImmunotherapyHumansTabletsRetrospective StudiesRisk AssessmentFemaleProduct Surveillance, PostmarketingPharmacovigilanceAdultMaleMiddle AgedYoung AdultAdolescent

Stichwörter der Autor:innen

GrastekGrazaxOdactraOralairRagwitekSLIT

Substanzen

Tablets

Autor:innen und Institutionen

  • Azienda Ospedaliero Universitaria Città Della Salute E Della Scienza Di Torino, Hospital Pharmacy, C.So Bramante 88, Turin, 10135, Piedmont, Italy. ecastellana@cittadellasalute.to.it.
  • Azienda Ospedaliero Universitaria Città Della Salute E Della Scienza Di Torino, Hospital Pharmacy, C.So Bramante 88, Turin, 10135, Piedmont, Italy.

Zitieren

APA

Castellana, E., & Chiappetta, M. R. (2026). Post-marketing safety evaluation and objective benefit-risk assessment of sublingual immunotherapy tablets in allergic rhinitis. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(9), 14595-14599. https://doi.org/10.1007/s00210-026-05307-8

Vancouver

Castellana E, Chiappetta MR. Post-marketing safety evaluation and objective benefit-risk assessment of sublingual immunotherapy tablets in allergic rhinitis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(9):14595-14599. doi:10.1007/s00210-026-05307-8

BibTeX
@article{Castellana2026,
  author = {Castellana, Eleonora and Chiappetta, Maria Rachele},
  title = {Post-marketing safety evaluation and objective benefit-risk assessment of sublingual immunotherapy tablets in allergic rhinitis},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  volume = {399},
  number = {9},
  pages = {14595--14599},
  doi = {10.1007/s00210-026-05307-8}
}
Kostenlos starten →